Tag: Uveal melanoma

Tebentafusp was the first-in-class T-cell receptor therapeutic to be approved by the FDA, representing a significant breakthrough in cancer treatment. This innovative immunotherapy, also known by its brand name Kimmtrak, is a targeted therapy for adults with unresectable or metastatic uveal melanoma.

Up to 90% of metastatic uveal melanoma cases are concentrated within the liver, making liver-directed therapy a critical need. **What is Hepzato?** It represents a significant advancement, offering a targeted chemotherapy delivery system to treat these unresectable liver metastases while minimizing the systemic exposure and side effects typically associated with traditional treatments.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) as the first T-cell receptor (TCR) therapeutic for a solid tumor, representing a significant advancement in oncology. So, **what is kimmtrak?** This bispecific fusion protein is indicated for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.